Clinical trials: Alzheimer Disease, At Risk
Alzheimer's Disease
Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease
Recent data show that marked cell damage precedes the clinical manifestation of Alzheimer's disease (AD). Hence, targeting populations at risk with pharmacological interventions is a possible strategy to lessen the burden of the…
- Trial name
- NCT00933608
- Testing
- memantine
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Functional Aging, Subjective Cognitive Concerns
A Multidimensional Behavioral Intervention for Those at Risk for Alzheimer's Dementia
This intervention is designed to promote enhanced use of compensation strategies including calendar and task list use, and organization systems, as well as increased engagement with brain health activities including physical…
- Conditions
- Functional Aging, Subjective Cognitive Concerns, Compensation Strategies, Brain Health Activities
- Trial name
- NCT03549078
- Testing
- Intervention
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Alzheimer's Disease
Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia
The purpose of this study is to determine the safety, tolerability and effect of JNJ-54861911 on level of amyloid-beta in Cerebrospinal Fluid (CSF) and plasma following 4 weeks of treatment in Japanese participants asymptomatic…
- Trial name
- NCT02360657
- Testing
- JNJ-54861911, 10 mg, JNJ-54861911, 50 mg
- Where
- 2 sites in Japan
- Volunteers
- 18 people
- Sponsor
- Janssen Pharmaceutical K.K.
Alzheimers Disease
A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)
A study to evaluate the efficacy and safety of gantenerumab in amyloid-positive, cognitively unimpaired participants at risk for or at the earliest stages of AD.
- Trial name
- SKYLINE (NCT05256134)
- Testing
- Gantenerumab
- Where
- 63 sites in United States, Argentina and 8 more
- Volunteers
- 25 people
- Sponsor
- Hoffmann-La Roche
Alzheimer Disease
Study of Tau Imaging With the Use of [18F]MK-6240 Tracer
The recent development of a PET tracer,[18F]MK-6240(an[18F]tau imaging agent,CerveauTechnologies)that has high affinity for the human phosphorylated tau deposits in AD brain offers new opportunities to investigate tau pathology.
- Trial name
- MKADAD (NCT04104659)
- Testing
- MK 6240
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Tammie L. S. Benzinger, MD, PhD
Dementia Prevention, Subjective Cognitive Impairment
The Brain Health PRO Online Risk Factor Reduction Study to Prevent Dementia
This study will recruit participants at risk for dementia to participate in an online educational program called Brain Health PRO (BHPro).
- Conditions
- Dementia Prevention, Subjective Cognitive Impairment, Mild Cognitive Impairment, Cognitive Change
- Trial name
- BHPROOF (NCT07364019)
- Testing
- Brain Health PRO
- Where
- Canada
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Alzheimer Disease
Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease
The main purpose of this study is to evaluate the effects of donanemab (LY3002813) versus placebo in Chinese participants who are at risk for decline of memory, language and physical ability to perform activities of daily living…
- Trial name
- NCT07571161
- Testing
- Donanemab
- Where
- 30 sites in China
- Volunteers
- 140 people
- Sponsor
- Eli Lilly and Company
Hippocampal Hyperactivation, Prodromal Alzheimer Disease
Levetiracetam for Persons at Risk for Alzheimer's Disease
The goal of this clinical trial is to investigate whether very small doses of a drug called levetiracetam (LEV) may reduce elevated brain signaling in individuals who are at an increased risk for developing Alzheimer's Disease…
- Trial name
- ALEVIATE-2 (NCT07477431)
- Testing
- Levetiracetam (LEV)
- Where
- 2 sites in Canada
- Volunteers
- 40 people
- Sponsor
- Sunnybrook Health Sciences Centre
Dementia, Alzheimer Disease
A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment
The purpose of this study is to evaluate the efficacy and safety of galantamine treatment in patients with mild cognitive impairment.
- Trial name
- NCT00236431
- Testing
- Galantamine hydrobromide
- Volunteers
- 1,063 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Mild Cognitive Impairment
CBD for Individuals at Risk for Alzheimer's Disease
This is a double-blind, randomized controlled trial designed to test the effects of cannabidiol (CBD) on validated biomarkers of Alzheimer's disease (AD) progression, and behavioral, neurocognitive, and clinical measures, with…
- Trial name
- NCT05822362
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 236 people
- Sponsor
- University of Colorado, Denver
Glucose Metabolism Disorders (Including Diabetes Mellitus), Cognitive Decline
Glucose Variability and Cognition in Prediabetes
This study examines the association of variability in glucose values over a 10-day period with cognitive function and AD risk markers among individuals with prediabetes, aged 50 or older.
- Conditions
- Glucose Metabolism Disorders (Including Diabetes Mellitus), Cognitive Decline, PreDiabetes, Aging
- Trial name
- NCT04201600
- Testing
- Continuous Glucose Monitoring System (CGMS)
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Mild Cognitive Impairment, Alzheimer Disease
Cognitive Vulnerability to Stress in Individuals at Risk for Alzheimer's Disease
The goal of this clinical trial is to learn about how genetics and the response to stress predicts cognitive decline in individuals with mild cognitive impairment.
- Trial name
- Stress-AD (NCT05795634)
- Testing
- Trier Social Stress Test
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Johns Hopkins University
Healthy, Mild Cognitive Impairment
Does Acoustic Stimulation During Sleep Boost Slow Wave Sleep and Memory Performance?
With aging the amount of slow wave sleep decreases drastically and this disruption is markedly exaggerated in older adults suffering from mild cognitive impairment and Alzheimer's disease.
- Conditions
- Healthy, Mild Cognitive Impairment, Alzheimer Disease
- Trial name
- NCT04277104
- Testing
- Closed loop acoustic stimulation
- Where
- Switzerland
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- University of Bern
Mild Cognitive Impairment, Alzheimer Dementia
Exercise, Brain, Cognition, OMICs, Molecular Markers and Functionality in People at Risk of Mild Cognitive Impairment
This project aims to examine the effect of a 5-month period supervised exercise intervention on brain, cognition, OMICs, Molecular Markers and functional status in older people at risk of mild cognitive impairment.
- Trial name
- NCT03923712
- Testing
- Supervised Exercise Programme
- Where
- Spain
- Volunteers
- 98 people
- Sponsor
- University of Cadiz
Aging
Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease
The purpose of this pilot study is to demonstrate the safety and feasibility of administering intermittent doses of Dasatinib and Quercetin (D+Q) in older adults at risk of Alzheimer's disease (AD).
- Trial name
- STAMINA (NCT05422885)
- Testing
- Dasatinib, Quercetin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Lewis Lipsitz
Alzheimer Disease
Epidemiology and Biomarker Study in Alzheimer's Disease
Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.
- Trial name
- ANCHOR-AD (NCT07142954)
- Testing
- P-tau217 Test
- Where
- 4 sites in United States, Japan
- Volunteers
- 3,400 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer Disease, Dementia
ANNE Vital Sign System Remote Sleep Assessment
Sleep apnea is characterized by temporary pauses or stops to participant's breathing. Currently, sleep apnea is diagnosed using an in-lab sleep study, which involves spending a night in a sleep laboratory hooked up to wires on…
- Conditions
- Alzheimer Disease, Dementia, Mild Cognitive Impairment, Sleep Apnea
- Trial name
- NCT05669495
- Testing
- ANNE Vital Sign System
- Where
- Canada
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Sunnybrook Health Sciences Centre
Alzheimers Disease, Dementia
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with…
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Trial name
- DIAN-TU (NCT01760005)
- Testing
- Gantenerumab, Solanezumab, E2814
- Where
- 38 sites in United States, Argentina and 13 more
- Volunteers
- 490 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Aging, Alzheimer's Disease
Effects of Exercise and Cognitive Training on Cognitive Function in Older Adults
The purpose of this study is to gain a better understanding of the effects of exercise and cognitive training on improving brain function in healthy older adults who may be at risk for developing Alzheimer's Disease.
- Trial name
- NCT01038726
- Testing
- Exercise Training, Cognitive Training, Flexibility Training
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
At Risk for AD-dementia, With Subjective Cognitive Decline, At Risk for Cognitive Decline
High-Velocity Resistance Training for Brain Blood Flow and Cognitive Function in Older Adults
The goal of this clinical trial is to learn whether a 12-week high-velocity resistance training program can improve brain blood flow and thinking skills in adults ages 60 to 79 who are at higher risk for Alzheimer's disease and…
- Trial name
- NCT07444554
- Testing
- High-Velocity Resistance Training
- Volunteers
- 60 people
- Sponsor
- University of Illinois at Chicago